Cargando…

Association between mirtazapine use and serious self-harm in people with depression: an active comparator cohort study using UK electronic health records

BACKGROUND: Studies report an increased risk of self-harm or suicide in people prescribed mirtazapine compared with other antidepressants. OBJECTIVES: To compare the risk of serious self-harm in people prescribed mirtazapine versus other antidepressants as second-line treatments. DESIGN AND SETTING:...

Descripción completa

Detalles Bibliográficos
Autores principales: Joseph, Rebecca M, Jack, Ruth H, Morriss, Richard, Knaggs, Roger David, Butler, Debbie, Hollis, Chris, Hippisley-Cox, Julia, Coupland, Carol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9685727/
https://www.ncbi.nlm.nih.gov/pubmed/35246454
http://dx.doi.org/10.1136/ebmental-2021-300355
_version_ 1784835575901061120
author Joseph, Rebecca M
Jack, Ruth H
Morriss, Richard
Knaggs, Roger David
Butler, Debbie
Hollis, Chris
Hippisley-Cox, Julia
Coupland, Carol
author_facet Joseph, Rebecca M
Jack, Ruth H
Morriss, Richard
Knaggs, Roger David
Butler, Debbie
Hollis, Chris
Hippisley-Cox, Julia
Coupland, Carol
author_sort Joseph, Rebecca M
collection PubMed
description BACKGROUND: Studies report an increased risk of self-harm or suicide in people prescribed mirtazapine compared with other antidepressants. OBJECTIVES: To compare the risk of serious self-harm in people prescribed mirtazapine versus other antidepressants as second-line treatments. DESIGN AND SETTING: Cohort study using anonymised English primary care electronic health records, hospital admission data and mortality data with study window 1 January 2005 to 30 November 2018. PARTICIPANTS: 24 516 people diagnosed with depression, aged 18–99 years, initially prescribed a selective serotonin reuptake inhibitor (SSRI) and then prescribed mirtazapine, a different SSRI, amitriptyline or venlafaxine. MAIN OUTCOME MEASURES: Hospitalisation or death due to deliberate self-harm. Age–sex standardised rates were calculated and survival analyses were performed using inverse probability of treatment weighting to account for baseline covariates. RESULTS: Standardised rates of serious self-harm ranged from 3.8/1000 person-years (amitriptyline) to 14.1/1000 person-years (mirtazapine). After weighting, the risk of serious self-harm did not differ significantly between the mirtazapine group and the SSRI or venlafaxine groups (HRs (95% CI) 1.18 (0.84 to 1.65) and 0.85 (0.51 to 1.41) respectively). The risk was significantly higher in the mirtazapine than the amitriptyline group (3.04 (1.36 to 6.79)) but was attenuated after adjusting for dose. CONCLUSIONS: There was no evidence for a difference in risk between mirtazapine and SSRIs or venlafaxine after accounting for baseline characteristics. The higher risk in the mirtazapine versus the amitriptyline group might reflect residual confounding if amitriptyline is avoided in people considered at risk of self-harm. CLINICAL IMPLICATIONS: Addressing baseline risk factors and careful monitoring might improve outcomes for people at risk of serious self-harm.
format Online
Article
Text
id pubmed-9685727
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-96857272022-11-25 Association between mirtazapine use and serious self-harm in people with depression: an active comparator cohort study using UK electronic health records Joseph, Rebecca M Jack, Ruth H Morriss, Richard Knaggs, Roger David Butler, Debbie Hollis, Chris Hippisley-Cox, Julia Coupland, Carol Evid Based Ment Health Adult Mental Health BACKGROUND: Studies report an increased risk of self-harm or suicide in people prescribed mirtazapine compared with other antidepressants. OBJECTIVES: To compare the risk of serious self-harm in people prescribed mirtazapine versus other antidepressants as second-line treatments. DESIGN AND SETTING: Cohort study using anonymised English primary care electronic health records, hospital admission data and mortality data with study window 1 January 2005 to 30 November 2018. PARTICIPANTS: 24 516 people diagnosed with depression, aged 18–99 years, initially prescribed a selective serotonin reuptake inhibitor (SSRI) and then prescribed mirtazapine, a different SSRI, amitriptyline or venlafaxine. MAIN OUTCOME MEASURES: Hospitalisation or death due to deliberate self-harm. Age–sex standardised rates were calculated and survival analyses were performed using inverse probability of treatment weighting to account for baseline covariates. RESULTS: Standardised rates of serious self-harm ranged from 3.8/1000 person-years (amitriptyline) to 14.1/1000 person-years (mirtazapine). After weighting, the risk of serious self-harm did not differ significantly between the mirtazapine group and the SSRI or venlafaxine groups (HRs (95% CI) 1.18 (0.84 to 1.65) and 0.85 (0.51 to 1.41) respectively). The risk was significantly higher in the mirtazapine than the amitriptyline group (3.04 (1.36 to 6.79)) but was attenuated after adjusting for dose. CONCLUSIONS: There was no evidence for a difference in risk between mirtazapine and SSRIs or venlafaxine after accounting for baseline characteristics. The higher risk in the mirtazapine versus the amitriptyline group might reflect residual confounding if amitriptyline is avoided in people considered at risk of self-harm. CLINICAL IMPLICATIONS: Addressing baseline risk factors and careful monitoring might improve outcomes for people at risk of serious self-harm. BMJ Publishing Group 2022-11 2022-03-04 /pmc/articles/PMC9685727/ /pubmed/35246454 http://dx.doi.org/10.1136/ebmental-2021-300355 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
spellingShingle Adult Mental Health
Joseph, Rebecca M
Jack, Ruth H
Morriss, Richard
Knaggs, Roger David
Butler, Debbie
Hollis, Chris
Hippisley-Cox, Julia
Coupland, Carol
Association between mirtazapine use and serious self-harm in people with depression: an active comparator cohort study using UK electronic health records
title Association between mirtazapine use and serious self-harm in people with depression: an active comparator cohort study using UK electronic health records
title_full Association between mirtazapine use and serious self-harm in people with depression: an active comparator cohort study using UK electronic health records
title_fullStr Association between mirtazapine use and serious self-harm in people with depression: an active comparator cohort study using UK electronic health records
title_full_unstemmed Association between mirtazapine use and serious self-harm in people with depression: an active comparator cohort study using UK electronic health records
title_short Association between mirtazapine use and serious self-harm in people with depression: an active comparator cohort study using UK electronic health records
title_sort association between mirtazapine use and serious self-harm in people with depression: an active comparator cohort study using uk electronic health records
topic Adult Mental Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9685727/
https://www.ncbi.nlm.nih.gov/pubmed/35246454
http://dx.doi.org/10.1136/ebmental-2021-300355
work_keys_str_mv AT josephrebeccam associationbetweenmirtazapineuseandseriousselfharminpeoplewithdepressionanactivecomparatorcohortstudyusingukelectronichealthrecords
AT jackruthh associationbetweenmirtazapineuseandseriousselfharminpeoplewithdepressionanactivecomparatorcohortstudyusingukelectronichealthrecords
AT morrissrichard associationbetweenmirtazapineuseandseriousselfharminpeoplewithdepressionanactivecomparatorcohortstudyusingukelectronichealthrecords
AT knaggsrogerdavid associationbetweenmirtazapineuseandseriousselfharminpeoplewithdepressionanactivecomparatorcohortstudyusingukelectronichealthrecords
AT butlerdebbie associationbetweenmirtazapineuseandseriousselfharminpeoplewithdepressionanactivecomparatorcohortstudyusingukelectronichealthrecords
AT hollischris associationbetweenmirtazapineuseandseriousselfharminpeoplewithdepressionanactivecomparatorcohortstudyusingukelectronichealthrecords
AT hippisleycoxjulia associationbetweenmirtazapineuseandseriousselfharminpeoplewithdepressionanactivecomparatorcohortstudyusingukelectronichealthrecords
AT couplandcarol associationbetweenmirtazapineuseandseriousselfharminpeoplewithdepressionanactivecomparatorcohortstudyusingukelectronichealthrecords